Skip to main content
SHANGHAI MICURX PHARMACEUTICAL CO., LTD. logo

SHANGHAI MICURX PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 688373 ISIN · CNE100005PX4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 452 across all filing types
Latest filing 2026-06-02 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688373

About SHANGHAI MICURX PHARMACEUTICAL CO., LTD.

https://www.micurxchina.com/

Shanghai MicuRx Pharmaceutical Co., Ltd. specializes in the discovery, development, and commercialization of innovative anti-infective therapeutics designed to combat multi-drug resistant (MDR) bacterial pathogens. The company’s primary focus is the development of next-generation antibiotics with improved safety profiles. Its lead commercial product, contezolid (MRX-I), is an oxazolidinone antibiotic indicated for complex skin and soft tissue infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The research pipeline includes MRX-4, a prodrug of contezolid, and MRX-8, a novel therapeutic targeting Gram-negative "superbugs." By utilizing a proprietary drug discovery platform, the company aims to provide effective treatment options for serious infectious diseases while reducing common toxicities associated with traditional antibiotic classes.

Recent filings

Filing Released Lang Actions
上海盟科药业股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is the official announcement of the resolutions and voting results from the company’s 2025 Annual General Meeting. It provides detailed vote counts, approval ratios, meeting attendance, and lawyer confirmation, fitting the definition of Declaration of Voting Results & Voting Rights Announcements.
2026-06-02 Chinese
上海市方达律师事务所关于上海盟科药业股份有限公司2025年年度股东会的法律意见书
Legal Proceedings Report Classification · 85% confidence The document is a formal legal opinion (“法律意见书”) issued by Fangda Partners regarding the convening, procedures, participant qualifications and voting results of the 2025 annual shareholders’ meeting of Shanghai Mengke Pharma. It is not a financial report, proxy statement, earnings release or management presentation—rather it is a legal opinion on the legality of the AGM procedures and results. This falls under Legal Proceedings Report/Information (LTR).
2026-06-02 Chinese
上海盟科药业股份有限公司2025年年度股东会会议资料
AGM Information Classification · 91% confidence The document is titled “2025年年度股东会会议资料” (2025 Annual General Meeting Materials). It comprises meeting instructions, agenda, proposals, board work report, and related attachments for the AGM itself. This is not an announcement or proxy notice but the actual materials presented at the Annual General Meeting. Therefore it falls under “AGM Information,” code AGM-R.
2026-05-26 Chinese
上海盟科药业股份有限公司关于股东减持计划时间届满暨减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from Shanghai Mengke Pharmaceutical Co., Ltd. regarding the expiration of a shareholder share reduction plan and the results of the share reduction. It details the shareholders involved, their holdings before and after the plan, the planned and actual reduction amounts, and confirms that no shares were actually reduced during the plan period. The document includes specific dates, shareholder names, share quantities, and compliance statements. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about shareholding changes and compliance with reduction plans. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or results related to significant share ownership levels and shareholder actions. The document length is under 5,000 characters and is a detailed announcement, not a brief report publication notice or a certification. Therefore, the appropriate classification is MRQ with high confidence.
2026-05-06 Chinese
上海盟科药业股份有限公司关于董事和高级管理人员2026年度薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 annual remuneration scheme for the company's directors and senior management. It details the salary structure, performance linkage, and approval process by the board and remuneration committee. It does not contain financial statements or performance results but focuses on compensation policy and governance related to executive pay. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-04-28 Chinese
上海盟科药业股份有限公司关于完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Mengke Pharmaceutical Co., Ltd. regarding the completion of industrial and commercial registration changes and the issuance of a new business license. It references a previous announcement about changes in registered capital and amendments to the company charter. The content focuses on corporate registration updates and legal compliance rather than financial results, management changes, or shareholder votes. The document length is short (807 characters) and it is an official announcement of a corporate registration update, not a financial report or detailed management report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.